NASDAQ:ZYME Zymeworks Q2 2026 Earnings Report $27.12 +0.60 (+2.26%) Closing price 09/28/2026 04:00 PM EasternExtended Trading$27.78 +0.66 (+2.43%) As of 09/28/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Zymeworks EPS ResultsActual EPS-$0.62Consensus EPS -$0.56Beat/MissMissed by -$0.06One Year Ago EPS$0.03Zymeworks Revenue ResultsActual Revenue$3.23 millionExpected Revenue$4.54 millionBeat/MissMissed by -$1.31 millionYoY Revenue Growth-90.60%Zymeworks Announcement DetailsQuarterQ2 2026Date8/7/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:00PM ETUpcoming EarningsZymeworks' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zymeworks Earnings HeadlinesZymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 GuidanceSeptember 28 at 3:17 PM | finance.yahoo.comZymeworks Inc. Updates Earnings Guidance for the Year 2026September 28 at 12:47 PM | marketscreener.comMALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Zymeworks Appoints Stuart Knight as Executive Vice President & Chief Information OfficerSeptember 28 at 12:47 PM | marketscreener.comMZymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - SlideshowSeptember 28 at 9:01 AM | seekingalpha.comZymeworks Issues Updated 2026 Financial GuidanceSeptember 28 at 7:46 AM | rttnews.comSee More Zymeworks Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zymeworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zymeworks and other key companies, straight to your email. Email Address About ZymeworksZymeworks (NASDAQ:ZYME) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company uses its proprietary Azymetric and EFECT antibody-engineering platforms to design multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates intended to address complex disease biology. Zymeworks’ leading product is zanidatamab, a bispecific antibody targeting HER2. In the United States, zanidatamab is marketed as Ziiたhera for previously treated, unresectable or metastatic HER2-positive biliary tract cancer. Jazz Pharmaceuticals is responsible for commercialization under a global licensing and collaboration agreement, while Zymeworks continues to receive development-related benefits and advances additional applications of the therapy. Founded in 2003, Zymeworks is headquartered in Vancouver, British Columbia, and maintains operations in the United States. In addition to zanidatamab, the company is developing a pipeline of investigational antibody-based therapies for oncology and other therapeutic areas. Kenneth Galbraith serves as chief executive officer, having previously held senior commercial and business-development roles in the biopharmaceutical industry.View Zymeworks ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
